• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 4. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

8-(Azetidin-3-yloxy)Quinoline Dihydrochloride: A Comprehensive Overview

8-(Azetidin-3-yloxy)Quinoline Dihydrochloride (CAS No. 1449117-70-7) is a structurally unique compound that has garnered significant attention in the fields of organic chemistry and pharmacology. This compound, characterized by its quinoline backbone and azetidine substituent, represents a promising avenue for drug discovery and development. The quinoline moiety, a heterocyclic aromatic system, is well-known for its diverse biological activities, while the azetidine ring introduces additional complexity and potential for functionalization. Recent advancements in synthetic methodologies and computational modeling have further enhanced our understanding of this compound's properties and applications.

The synthesis of 8-(Azetidin-3-yloxy)Quinoline Dihydrochloride involves a multi-step process that combines traditional organic synthesis techniques with modern catalytic strategies. Researchers have explored various routes, including Suzuki-Miyaura coupling reactions and nucleophilic aromatic substitution, to optimize the yield and purity of this compound. The use of transition metal catalysts has been particularly effective in facilitating key steps, such as the formation of the azetidine ring and its subsequent attachment to the quinoline core. These advancements not only improve the scalability of the synthesis but also pave the way for further structural modifications to explore its pharmacological potential.

Recent studies have highlighted the antimicrobial properties of 8-(Azetidin-3-yloxy)Quinoline Dihydrochloride, particularly against multidrug-resistant bacterial strains. This compound exhibits potent activity against gram-positive and gram-negative bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA). Its mechanism of action involves disrupting bacterial cell membranes and inhibiting key enzymatic processes, making it a compelling candidate for antibiotic development. Furthermore, preclinical trials have demonstrated its ability to reduce inflammation in models of chronic diseases, suggesting potential applications in anti-inflammatory therapy.

The pharmacokinetic profile of 8-(Azetidin-3-yloxy)Quinoline Dihydrochloride has also been extensively investigated. Studies indicate that this compound has favorable absorption characteristics, with rapid uptake in the gastrointestinal tract and moderate plasma protein binding. Its half-life is sufficiently long to allow for once-daily dosing, which enhances patient compliance in clinical settings. However, further research is needed to fully characterize its metabolism and excretion pathways, particularly in relation to potential drug-drug interactions.

In terms of therapeutic applications, 8-(Azetidin-3-yloxy)Quinoline Dihydrochloride holds promise in several therapeutic areas beyond antimicrobial therapy. Its ability to modulate cellular signaling pathways makes it a potential candidate for cancer treatment, particularly in targeting pathways involved in tumor growth and metastasis. Additionally, early-stage research suggests that this compound may have neuroprotective effects, offering new possibilities for treating neurodegenerative diseases such as Alzheimer's disease.

The development of 8-(Azetidin-3-yloxy)Quinoline Dihydrochloride into a clinical drug candidate will require rigorous testing across various phases. Current efforts are focused on optimizing its bioavailability and minimizing off-target effects through structural modifications. Computational modeling tools, such as molecular docking and pharmacophore mapping, are being employed to guide these modifications and predict optimal drug-like properties.

In conclusion, 8-(Azetidin-3-yloxy)Quinoline Dihydrochloride (CAS No. 1449117-70-7) represents a significant advancement in medicinal chemistry with broad implications for drug discovery. Its unique structure, coupled with promising biological activities, positions it as a valuable asset in addressing unmet medical needs across multiple therapeutic areas. As research continues to uncover its full potential, this compound stands at the forefront of innovative approaches to combating infectious diseases, inflammation, and other debilitating conditions.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)